Literature DB >> 7512598

Definition of a DQ3.1-specific binding motif.

J Sidney1, C Oseroff, M F del Guercio, S Southwood, J I Krieger, G Y Ishioka, K Sakaguchi, E Appella, A Sette.   

Abstract

A quantitative peptide binding assay using purified DQA1*0301/DQB1*0301 (DQ3.1) molecules was developed and validated by examining the correlation between the data obtained in the binding assay with those obtained in inhibition of Ag presentation assays. By the combined use of large libraries of synthetic peptides and of substitution and truncation analogues, a putative DQ3.1 motif was defined. Its most prominent feature is the requirement for two small and/or hydrophobic residues spaced at positions i + 2 and i + 4. This motif is quite different from the motif recognized by DR molecules, but similar to the motif previously defined for certain IA alleles (the putative mouse homologue of DQ). These data suggest that various class II isotypes have evolved to present different peptide structures to each other, thus maximizing the repertoire of different epitopes available to T cell scrutiny.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512598

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Peptide-binding motifs of the mixed haplotype Abetaz/Aalphad major histocompatibility complex class II molecule: a restriction element for auto-reactive T cells in (NZBxNZW)F1 mice.

Authors:  M Mine; S Koarada; T Sai; K Miyake; M Kimoto
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

2.  A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11.

Authors:  C I Pearson; A M Gautam; I C Rulifson; R S Liblau; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

3.  Peptide binding characteristics of the coeliac disease-associated DQ(alpha1*0501, beta1*0201) molecule.

Authors:  Y van de Wal; Y M Kooy; J W Drijfhout; R Amons; F Koning
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

4.  Critical contribution of beta chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules.

Authors:  B S Nepom; G T Nepom; M Coleman; W W Kwok
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  PRBAM: a new tool to analyze the MHC class I and HLA-DR anchor motifs.

Authors:  Anna Mestre-Ferrer; Erika Scholz; Jepi Humet-Alsius; Iñaki Alvarez
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

6.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

7.  Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population.

Authors:  John Sidney; Amiyah Steen; Carrie Moore; Sandy Ngo; Jolan Chung; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

8.  Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes.

Authors:  Jason Greenbaum; John Sidney; Jolan Chung; Christian Brander; Bjoern Peters; Alessandro Sette
Journal:  Immunogenetics       Date:  2011-02-09       Impact factor: 2.846

9.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.

Authors:  B Rehermann; P Fowler; J Sidney; J Person; A Redeker; M Brown; B Moss; A Sette; F V Chisari
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  HLA-DQB1 codon 57 is critical for peptide binding and recognition.

Authors:  W W Kwok; M E Domeier; M L Johnson; G T Nepom; D M Koelle
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.